Ronald Ryder, DO
Cardiovascular Disease · Hamilton, NJNPI 1154309532
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $80,192 of the $90,670 with a category attached, or 88.4%. Amarin Pharma, Inc. accounts for 69.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2019 at $54,649 and has fallen 98.8% since, to $649 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 527 payments — averaging $172.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$63K
- Johnson & Johnson$13K
- Bayer$7K
- Esperion Therapeutics, Inc.$2K
- Kowa Pharmaceuticals America, Inc.$1K
- Amgen$626
- plus $4K from 29 others
What the payments were for
- Speaking & faculty fees$80,19288%
- Travel & lodging$1,5762%
- Food & beverage$8,89810%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 55 | $63,286 |
| Johnson & Johnson | 87 | $13,030 |
| Bayer | 18 | $7,112 |
| Esperion Therapeutics, Inc. | 3 | $1,647 |
| Kowa Pharmaceuticals America, Inc. | 89 | $1,398 |
| Amgen | 42 | $626 |
| Pfizer | 40 | $519 |
| Boston Scientific | 26 | $478 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $329 |
| Novartis | 50 | $328 |
| AstraZeneca | 16 | $224 |
| E.r. Squibb & Sons, L.L.C. | 13 | $178 |
| Novo Nordisk | 10 | $176 |
| Merck | 10 | $145 |
| Alnylam Pharmaceuticals Inc. | 8 | $119 |
| Kestra Medical Technology Services, Inc. | 3 | $113 |
| Regeneron Healthcare Solutions, Inc. | 6 | $102 |
| Scpharmaceuticals Inc. | 5 | $102 |
| United Therapeutics Corporation | 4 | $98 |
| Actelion Pharmaceuticals US, Inc. | 6 | $96 |
| Altathera Pharmaceuticals LLC | 4 | $95 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $69 |
| Bridgebio Pharma, Inc. | 4 | $67 |
| Arbor Pharmaceuticals, Inc. | 4 | $61 |
| Philips North America LLC | 2 | $58 |
| Daiichi Sankyo Inc. | 3 | $41 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Impulse Dynamics (USA) Inc. | 1 | $25 |
| Medicure Pharma Inc. | 1 | $23 |
| Atricure, Inc. | 1 | $23 |
| Edwards Lifesciences | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| CMP Pharma, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,670 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 908 | $1,076,453 |
| EliquisApixaban | 372 | $432,433 |
| EntrestoSacubitril/Valsartan | 158 | $198,175 |
| Icosapent Ethyl | 286 | $131,230 |
| VascepaIcosapent Ethyl | 158 | $128,253 |
| Repatha SureclickEvolocumab | 99 | $111,006 |
| MultaqDronedarone Hcl | 58 | $101,315 |
| FarxigaDapagliflozin Propanediol | 98 | $100,086 |
| BrilintaTicagrelor | 57 | $55,646 |
| Pitavastatin Calcium | 57 | $24,860 |
| Metoprolol Succinate | 1,490 | $23,649 |
| Praluent PenAlirocumab | 20 | $23,558 |
| JardianceEmpagliflozin | 24 | $20,130 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 384 | $19,636 |
| LivaloPitavastatin Calcium | 19 | $17,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $13,030 | $1,076,453908 claims |
| PfizerEliquis | $519 | $432,433372 claims |
| NovartisEntresto | $328 | $198,175158 claims |
| AstraZenecaFarxiga, Brilinta | $224 | $155,732155 claims |
| Sanofi-aventis U.S. LLCMultaq | $25 | $101,31558 claims |
| Boehringer IngelheimJardiance | $17 | $20,13024 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $1,398 | $17,48519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Hamilton
- Edward WingfieldHamilton$125K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.